The company provides cost-effective pharmaceuticals and focuses on three fields: generic products, niche products and original drugs. BioPhausia focuses on marketing and sales. BioPhausia has no research program at the present time. BioPhausia is a Specialty Pharma company, buying or licensing pharmaceuticals with or without patent to market and sell. Further, BioPhausia is looking for potential partners within the biotech sector to take part in the development of new original drugs. The goal for BioPhausia is to become a leading Specialty Pharma company in the Nordic area, with an extensive product portfolio of original drugs as well as generics, to competitive prices. As a public company, BioPhausia shall be an attractive investment for investors interested in taking the opportunity of a fast growing selected niche market of Specialty Pharma. One of the most important strengths of BioPhausia is the small and effective organisation, with a management team with long experience of working within the pharmaceutical industry. BioPhausia works with well-developed processes; from selecting new products through the regulatory process to introducing the product to the market. Because of the established processes BioPhausia is able to handle substantial volumes and market a large number of products, with a small and focused organisation. BioPhausia markets and sells generic products through the subsidiary BMM Pharma. The generic products are bioequivalent with each original product respectively.

Core Sales Territory: All of Europe

Core Operation: API Manufacture, Finished Dose Manufacture, Sales and Marketing

Number of molecules sold: 30

Company's rating: